We sought a regimen that incorporates optimal novel agents and balances efficacy with toxicity in transplant-ineligible multiple myeloma (MM) patients. Our study evaluated modified lenalidomide-bortezomib-dexamethasone (RVD lite) in this population and was administered over a 35-day cycle. Lenalidomide 15 mg was given orally on days 1-21; bortezomib 1Á3 mg/m 2 weekly subcutaneously on days 1, 8, 15 and 22; and dexamethasone 20 mg orally was given on the day of and day after bortezomib for 9 cycles followed by 6 cycles of consolidation with lenalidomide and bortezomib. The primary objective was to evaluate the overall response rate (ORR); secondary objectives included safety, progression-free survival (PFS) and overall survival (OS). Fifty-three eligible patients were screened between April 2013 and May 2015; 50 received at least one dose of therapy. Median age at study entry was 73 years (range 65-91). The ORR was 86% and 66% of patients achieved a very good partial response or better. Median PFS was 35Á1 months (95% confidence interval 30Á9-not reached) and median OS was not reached at a median follow-up of 30 months. Peripheral neuropathy was reported in 31 (62%) patients with only 1 patient experiencing grade 3 symptoms. RVD lite is a well-tolerated and highly effective regimen, with robust PFS and OS, in the transplant-ineligible MM population.
Multiple myeloma (MM) is a malignant proliferation of plasma cells. It is the second most common haematological malignancy, accounting for an estimated 30 280 cases and 12 590 deaths in the US in 2017 (Siegel et al, 2017) . MM is a disease of older adults with a median age at diagnosis of 66 years (Kyle et al, 2003) . Over the last 10 years, autologous stem cell transplantation (ASCT) and the availability of effective new drugs, such as the immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide) and the proteasome inhibitors (bortezomib, carfilzomib and ixazomib), have greatly advanced treatment paradigms and improved the quality and duration of life for patients with this disease. However, the survival benefits are limited in elderly or frail individuals with MM. This may be a reflection of associated comorbidities in the older patient population, differences in disease biology, as well as the lack of participation in clinical trials because of the intensity of the visit schedule (Kumar et al, 2014) .
Melphalan and prednisone-based regimens have historically been the most widely accepted treatment option in the older population ineligible for high-dose therapy since the 1960s (Facon et al, 2006) . More recent data from the FIRST (Frontline Investigation of Revlimid and Dexamethasone versus Standard Thalidomide) trial established continuous lenalidomide and dexamethasone (Rd) as the new standard of care for transplant-ineligible patients with newly-diagnosed MM (NDMM) (Benboubker et al, 2014) . Motivated by in vitro data showing synergistic activity between bortezomib and lenalidomide (Mitsiades et al, 2002) , a major step forward has been combining lenalidomide, bortezomib and dexamethasone (RVD) (Richardson et al, 2010; Kumar et al, 2012) . Among patients treated at the maximum tolerated dose of lenalidomide (25 mg days 1-14), bortezomib (1Á3 mg/m 2 intravenously days 1, 4, 8, 11) and dexametha-cycle), the overall response rate (ORR) was 100% with very good partial response (VGPR) or better seen in 74% patients. The Southwest Oncology Group (SWOG) study S0777 validated this triplet regimen, showing superior progression-free survival (PFS), overall survival (OS) and ORR with the triplet combination of RVD versus the doublet combination of Rd alone in patients with NDMM without intention for immediate ASCT (Durie et al, 2017) . However, the dosing schedule of RVD may be more challenging for older patients. Dose reductions were required in all patients older than 75 years in this trial (N = 4) (Richardson et al, 2010; Durie et al, 2017) . A recently published phase II study of upfront lower-dose lenalidomide for relapsed, refractory (RR) MM supports the idea of treatment attenuation in older patients to minimize toxicity while maintaining efficacy (Quach et al, 2017) . In patients with RRMM treated with 15 mg of lenalidomide, the ORR was 71%, and the PFS and OS were 8Á9 and 30Á5 months, respectively. This compared favourably and without statistical difference from a matched cohort of patients from the phase III MM009/MM010 trial with a reduction in rates of neutropenia, infection and venous thromboembolism (Dimopoulos et al, 2009) .
With a view to exploit the synergy seen in preclinical and clinical studies and to maximize tolerability and convenience in transplant-ineligible NDMM patients, we proposed a reduction in the intensity of the RVD regimen, RVD lite, combining lenalidomide at a dose of 15 mg days 1-21; bortezomib 1Á3 mg/m 2 days 1, 8, 15 and 22 and dexamethasone 20 mg on the day of and the day after bortezomib on a 35-day cycle.
Methods

Study design and patients
In this phase II, single-arm, multicentre study, we prospectively investigated modified RVD (RVD lite) in transplant- Patients were excluded if they had received prior systemic therapy for MM, had a platelet count <50 9 10 9 /l, absolute neutrophil count (ANC) <1 9 10 9 /l, haemoglobin <80 g/l, hepatic impairment (total bilirubin ≤1Á5 9 the upper limit of normal (ULN); transaminases ≤2 9 ULN), renal insufficiency (defined as a serum creatinine >221 lmol/l, or peripheral neuropathy ≥ grade 2 on clinical examination. Females of child-bearing potential had to be on contraception during the study and have negative pregnancy tests before study enrolment. The primary endpoint was ORR. Secondary endpoints included safety, toxicity, PFS, OS, time to response, health-related quality of life (HRQoL), as well as, the pharmacokinetic profile of intravenous (IV) versus subcutaneous (SC) administration of bortezomib in combination with lenalidomide and dexamethasone. All patients provided written informed consent. This study was approved by the Institutional Review Board at each of the participating sites. This trial was registered at clinicaltrials.gov (NCT01782963).
Treatment
Patients received lenalidomide 15 mg orally once daily on days 1-21; bortezomib 1Á3 mg/m 2 SC on days 1, 8, 15 and 22; and dexamethasone 20 mg orally on days 1, 2, 8, 9, 15, 16, 22 and 23 for patients ≤75 years and days 1, 8, 15, 22 for patients older than 75 years of a 35-day cycle. The first 10 patients received bortezomib IV. Induction consisted of 9 cycles of this three-drug combination followed by 6 cycles of consolidation with lenalidomide 15 mg days 1-21 and bortezomib 1Á3 mg/m 2 days 1 and 15 on a 28-day cycle (Fig 1) . Lenalidomide maintenance was not mandated by the protocol but was continued at the discretion of the investigator until disease progression or the development of unacceptable side effects. Thromboprophylaxis with daily aspirin (81 mg or 325 mg) or low molecular weight heparin was required for all participants. Prophylaxis against herpes zoster with antivirals was also mandated during induction and consolidation cycles. Concomitant bisphosphonate therapy, according to institutional guidelines, was required during induction cycles.
Toxicity was assessed using the Cancer Therapy Evaluation Program (CTEP) Version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE) (https://evs.nci.nih. gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_ 5x7.pdf). Dose modifications or delays were based on the toxicity experienced during a cycle of therapy or newly encountered on day 1 of each cycle. Dose modifications for lenalidomide were pre-specified for renal insufficiency. Reduction and/or temporary suspension of one agent alone was allowed if toxicity was related primarily to one of the agents. Lenalidomide and bortezomib were held for ≥ grade 3 neutropenia or thrombocytopenia. Use of granulocyte-colony stimulating factor and platelet transfusions were allowed. For other lenalidomide or bortezomib-related non-haematological toxicity ≥ grade 3, the attribution of the toxicity was determined by the investigator and the appropriate therapy was held until resolution of the toxicity to grade 2 or less before resuming therapy with a one-level dose reduction.
Patients underwent blood count and serum chemistry monitoring on days 1, 8, 15 and 22 for the first two cycles and on day 1 of each cycle thereafter. Physical examination, serum and urine protein electrophoresis, and serum free light chains were performed on day 1 of each cycle. An independent data and safety monitoring committee reviewed safety and efficacy data throughout the study.
Assessment
Disease response to treatment was assessed using criteria based on the IMWG uniform response criteria (Durie et al, 2006; Rajkumar et al, 2011) . Responses were assessed on day 1 of each cycle. PFS was defined from the first day of study treatment to disease progression or death from any cause. Toxicity was assessed throughout the study. Plasma concentrations of bortezomib were measured pre-dose and at 5 min, 30 min and 5 h post-dose in 20 patients (10 SC, 10 IV). Age and weight were balanced between the two cohorts. Quality of life (QoL) measurements were conducted using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire -Core (QLQ-C30), the EORTC Multiple Myeloma (QLQ-MY20) module, and the Functional Assessment of Cancer Therapy/ Gynecologic Oncology Group-Neurotoxicity (FACT-NTX) side-effects questionnaires. Follow-up assessments were performed every 2 months. These assessments include serum and urine protein electrophoresis, serum and urine immunofixation, immunoglobulins assay and serum free light chain assay. At these assessments, participants were followed for disease status, survival and long-term toxicities. Once a patient progressed, disease assessments were no longer required.
Statistical analysis
The primary endpoint of this study was ORR after 4 cycles of RVD lite. An initial cohort of 10 eligible participants received IV bortezomib. This study used a Simon's two-stage design to allow for early termination of the study if the combination lacked efficacy. Treatment was considered effective among the 40 eligible participants if 25 or more eligible participants achieved a partial response. This design had at least an 87% chance of concluding the treatment was effective when the true response rate was 70% and less than a 10% chance of concluding the treatment was effective when the true response rate was 50% or less. With 40 eligible participants entered on study, the 90% exact binomial confidence interval width for toxicity and response was no wider than 28%.
Statistical analyses for this trial were performed using SAS (SAS Institute Inc. Cary, NC, USA) and R (R Core Team 2016). Patient characteristics were summarized using proportions for discrete data and median for continuous variables with comparisons between arms performed using Fisher's exact test for discrete data and Mann-Whitney rank sum for continuous data. Time-to-event outcomes were estimated using Kaplan-Meier methods and compared between groups using stratified log rank tests. Logistic regression models and Cox proportional hazard regression models were implemented to evaluate the impact of baseline information on response and time to event outcomes.
QLQ-C30 and QLQ-MY20 domains were scored in accordance with their published guidelines (Aaronson et al, 1993; Hjermstad et al, 1995; Cocks et al, 2007) . Results were transformed into scales ranging from 0 to 100 for QLQ-C30 and QLQ-MY20. For the functional scales (Global Health Status and Physical Functioning), higher scores indicate better HRQoL, whereas for the symptom scales (Fatigue, Pain, Disease Symptoms and Side Effects of Treatment), lower scores indicate a better health state.
Results
Patients
From 17 April 2013 to 20 May 2015, 53 eligible patients were screened at 5 sites; 50 patients received at least one dose of therapy. Median age at study entry was 73 years (range 65-91) and included 27 (54%) women and 23 (46%) men (Table I ). ECOG performance status of patients enrolled was 0 in 25 (50%), 1 in 18 (36%) and 2 in 7 (14%) patients. The International Staging System (ISS) stage was I in 19 (38%), II in 17 (34%) and III in 14 (28%) pts. High-risk cytogenetics, defined as the presence of deletion 17, t(4;14), t(14;16) and/or t(16;20) by fluorescence in situ hybridization, were identified in 6 (12%) patients.
Efficacy
Overall response rate. The primary endpoint was ORR after four cycles of RVD lite (Table II) . Fifty patients received at least one cycle of therapy. Three patients withdrew from the study after less than 1 cycle. Of these patients, one withdrew for worsened adrenal insufficiency, one for rash attributed to lenalidomide, and one was removed at the investigator's discretion for neurosurgical intervention. One additional patient completed 4 cycles of treatment but did not return for the cycle 5, day 1 visit so response was based on response after cycle 3. The ORR was 86% for the 50 patients, 66% of whom achieved a VGPR or better. Of the 46 patients evaluable for response after 4 cycles of therapy, the ORR was 94% and 72% achieved a VGPR or better. The median follow-up time was 30 months (95% confidence interval [CI], 25-33) based on inverse Kaplan-Meier estimation. Median PFS was 35Á1 months (95% CI, 30Á9-not reached) (Fig 2A) , and median OS (Fig 2B) was not reached. The median time to response was 1Á1 months. Sixty-six percent of patients received lenalidomide maintenance.
Safety. Table III lists the most commonly reported adverse events (AEs). Fatigue was the most commonly reported toxicity, occurring in 37 (74%) patients, and was mostly grade 1 or 2 in 29 (58%). Peripheral neuropathy of any grade was reported in 31 (62%) patients. Neuropathy appeared after a median of 6 cycles. Seventeen (34%) patients experience grade 1 and 9 (18%) grade 2 sensory peripheral neuropathy symptoms. Only one patient experienced grade 3 sensory neuropathy symptoms. Three patients (6%) reported grade 1 peripheral motor neuropathy and 3 (6%) grade 2 motor neuropathy. Upper respiratory infections occurred in 6 (12%) of patients. Grade 3 or greater toxicities occurring in 10% or more of patients included hypophosphataemia in 17 (34%), fatigue in 8 (16%), neutropenia in 7 (14%) and rash in 5 (10%) patients. Dose modifications occurred in 39 (78%) patients: dose reductions were made in 19 (38%) patients for bortezomib, 27 (54%) for lenalidomide, and 32 (64%) for dexamethasone. Two patients (4%) discontinued treatment due to toxicity. One patient developed a retinal artery thrombosis that was attributed to lenalidomide and the other patient developed grade 3 peripheral neuropathy attributed to bortezomib. that discontinued therapy prior to completion, 6 (12%) had progressive disease, 4 (8%) withdrew consent, 3 (6%) discontinued at the discretion of the investigator, 2 (4%) discontinued due to toxicity, 1 (2%) experienced a toxicity unrelated to study drug and was removed from study, 1 (2%) wished to travel for the winter and 1 (2%) switched to non-protocol therapy.
Pharmacokinetics. Plasma concentrations of bortezomib were significantly higher for the IV route, 98Á8 vs. 13Á0 mg/ml (P < 0Á0002) at 5 min, respectively, but higher for the SC route at 30 min, 20Á5 vs. 8Á73 ng/ml (P < 0Á0082). There was no significant difference in plasma concentrations of bortezomib at 5 h. In the SC route, high body mass index (BMI) patients tended to have low concentration at both the 5-and 30-min-measures, but not at 5 h. There was no correlation with BMI using the IV route (Table SI, Figure S1 ). There was no correlation between age and concentration level.
Patient-reported outcomes. Patient-reported QoL, functional, and symptom assessment scores comparing baseline and end of treatment were reported in 30 study patients (Fig 3,  Table SII ). At the end of treatment, there were statistically significant improvements in scores of physical functioning (P = 0Á013), future perspective (P = 0Á023) and disease symptoms (P = 0Á001) when compared to baseline. Patients reported fewer symptoms across all symptom domains with the exception of diarrhoea. EORTC global QoL scores showed improvement over the course of therapy although this did not reach statistical significance. There were no statistically significant changes in QoL using the FACT-GOG instrument over the course of treatment.
Discussion
One of the goals of treatment in newly-diagnosed patients is to achieve the deepest response possible, as outcomes correlate with depth of response. In this phase II study in transplantineligible NDMM, we showed that patients could be treated with dose-adjusted RVD (RVD lite) with comparable efficacy and better tolerability than standard induction RVD. This is all the more significant given the older patient population in our study. The ORR after 4 cycles of RVD lite was 86%, with 66% of patients achieving a VGPR or better. Putting our data in the context of other studies of the RVD combination, in the EVO-LUTION study, patients receiving RVD had an ORR of 85% and 51% achieved a VGPR or better after 4 cycles of RVD at standard doses (Kumar et al, 2012) . Ninety-four percent of these patients were considered transplant-eligible at the time of study entry. In the phase II portion of the single-arm study of RVD in NDMM the ORR was 100% with 74% achieving a VGPR or better after 4 cycles of therapy (Richardson et al, 2010) . Furthermore, in the SWOG S0777 study, the ORR in the cohort receiving RVD for 8 cycles was 82% with 43Á5% achieving a VGPR or better (Durie et al, 2017) . The median PFS in the SWOG study was superior at 43 months, however, this was a younger study population with a median age of 63 with only 43% of patients over the age of 65. Similarly, our results showed superior ORR and PFS compared to all oral combinations, which would conceptually be an attractive regimen for the older population, in two recent studies of ixazomib in combination with lenalidomide and dexamethasone in NDMM where transplant was either deferred or the patients were ineligible (Kumar et al, 2017; Richardson et al, 2017) ,. Specifically, when ixazomib was administered once weekly in combination with Rd, the ORR was 80% and the median PFS 25Á3 months in those not proceeding to SCT (Kumar et al, 2017) . With twice weekly ixazomib in combination with Rd, the ORR was 92%, however, the median PFS 24Á9 months for patients not proceeding to SCT (Richardson et al, 2017) . Acknowledging the limitation of drawing conclusions from the comparisons of trials with different investigation combinations, schedules and patient populations, our results do compare favourably with previous trials focusing specifically on transplant-ineligible patients. The median PFS in our study was 35Á1 months, which is the longest PFS reported in a trial of transplant-ineligible patients. By comparison, the FIRST Trial showed a PFS for continuous Rd of 25Á5 months. The median age for our trial was 73 years, which is the same as the FIRST trial. RVD lite also compares favourably with bortezomib-based combinations of bortezomib-thalidomide-dexamethasone (VTD), bortezomib-melphalan-prednisone (VMP), and bortezomib-dexamethasone examined in the transplantineligible population in the UPFRONT trial conducted in the community setting (Niesvizky et al, 2015) . In this trial, the longest median PFS was 17Á3 months for VMP and the best ORR was 80% for VTD. In the CLARION trial, 955 patients with NDMM were randomized to melphalan, prednisone and either carfilzomib or bortezomib on a twice-weekly schedule (Facon et al, 2017) . The median age of participants was 72 years. The ORRs were 84Á3% vs. 78Á8% (odds ratio [OR] = 1Á41; 95% CI 1Á01-1Á97), respectively, and the PFS was 22Á3 months (95% CI 20Á9-26Á7) in the carfilzomib arm, compared with 22Á1 months (95% CI 20Á8-24Á4) in the bortezomib arm, for a non-significant hazard ratio of 0Á906 (95% CI 0Á75-1Á1; P = 0Á159). Treatment discontinuation because of an AE occurred in 16Á7% of carfilzomib-treated patients and 14Á7% of bortezomib-treated patients.
RVD lite demonstrated excellent tolerability. Toxicities were generally manageable and were consistent with the types of toxicities reported historically with this combination. The only grade 3 toxicity noted in >10% of patients was hypophosphataemia, which was manageable and did not result in any dose modifications. Peripheral neuropathy of any kind was reported in 62% of patients with only one patient (2%) experiencing grade 3 symptoms. This compares favourably with twice weekly RVD with IV bortezomib reporting neuropathy in 80% of patients (Richardson et al, 2010) and the EVOLUTION study reporting grade 3 or greater neuropathy in 17% of patients (Kumar et al, 2012) . The reduction in rates and severity of peripheral neuropathy is probably the combination of the SC route of administration and the once weekly schedule. Though many patients did receive dose-modifications, this was done pro-actively to allow patients to continue therapy and is reflected in the very low discontinuation rate. The treatment discontinuation rate due to AEs from drug toxicity was low, at 4%. This study compared pharmacokinetics of SC versus IV administration in a subset of patients and supported previously reported findings that the SC route of administration was well-tolerated with excellent response rates and minimal high-grade peripheral neuropathy (Moreau et al, 2011) . Though the absolute rates of peripheral neuropathy in our trial exceeded that of both the SC and IV routes of administration in the trial reported by Moreau et al (2011) (5% SC and 15% IV), only one patient (2%) had grade 3 neuropathy.
RVD lite was associated with stable-to-improved HRQoL in patient-reported assessments. Few studies in MM have reported prospective HRQoL assessments to date. In the FIRST trial, comparing Rd with MPT (melphalan, predisone, thalidomide), HRQoL was a secondary endpoint. Overall, ccontinuous Rd was associated with a clinically meaningful improvement in HRQoL compared with MPT. In our study, statistically significant changes were also seen in physical functioning, future perspective and disease symptoms. Global health status improved though this did not meet statistical significance. It is recognized that, when analysing HRQoL data, a statistically significant change does not necessarily imply a clinically significant change. An assessment of minimal important difference (MID) can augment the interpretations of changes in HRQoL by translating statistical differences into clinically significant differences (King, 2011) . Pain associated with MM is a common and significant problem for this population. Though improvements in pain assessments did not meet statistical significance, the MID associated with pain did, and suggests a clinically significant improvement in this domain for this patient population as well (Kvam et al, 2010a,b; Delforge et al, 2015) . Though paired samples were only available for 30 out of the 50 enrolled patients, the overall finding support stable-toimproved HRQoL over the course of RVD lite therapy.
There are several limitations to this study. Specifically, it is a single-arm study that lacks a comparator arm. Further, the study did not mandate maintenance therapy, although the majority of patients (66%) did receive lenalidomide maintenance. This lack of standardization of maintenance therapy was largely due to the fact that the study was opened prior to the increasing use of lenalidomide as maintenance or continuous therapy.
RVD lite is a highly effective and well-tolerated regimen for previously untreated, transplant-ineligible MM patients and may represent the new standard of care for treating this patient population. We demonstrate that we can bring the benefits of more effective combination strategies observed in younger fitter transplant-eligible patients to older, transplantineligible patients with modifications in dose and schedule, without compromising efficacy. Ongoing studies are underway looking at other novel combinations in the transplantineligible population including trials of daratumumab, lenalidomide, and dexamethasone (NCT02252172) and ixazomib, lenalidomide, and dexamethasone (NCT01850524). An area of future exploration will be the addition of other novel therapies such as monoclonal antibodies to this regimen with the goal of creating a curative platform for the disease.
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